Osteopontin as a Biomarker in Pancreatitis

Completed

• Conditions: Pancreatitis
• Interventions: Other: No intervention, observation

• Registration Number: NCT05882500
• Lead Sponsor: Linkoeping University

Brief Summary

In the early phase of pancreatits, factors that can give information about the development of severety are still lacking. In this study patients will be included prospectively upon the diagnosis of pancreatits and clinical as well as labarotory and radiological factors will be sampled. The aim is do identifiy factors that may aid in the risk stratification for development of different severity grades of pancreatitis.

Detailed Description

In the early phase of pancreatits, factors that can give information about the development of severety are still lacking. In this study patients will be included prospectively upon the diagnosis of pancreatits and clinical as well as labarotory and radiological factors will be sampled. The aim is do identifiy factors that may aid in the risk stratification for development of different severity grades of pancreatitis.

Patients admitted and diagnosed with pancreatitis (according to the Atlanta criteria) will have serial testing of se-osteopontin in addiation to rutine blood work. Computet tomograpy and chest x-ray are mandatory as is blood culture.

Study Timeline

• Study Start: 2011-03-03
• Primary Completion: 2016-10-19
• Study Completion: 2023-01-31
• Status Verified: 2023-05
• Study First Submitted: 2023-05-11
• Study First Submitted QC: 2023-05-20
• Last Update Submitted: 2023-05-20
• Study First Posted: 2023-05-31
• Last Update Posted: 2023-05-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 103

Inclusion Criteria

• Diagnosis of pancreatitis

Exclusion Criteria

• Pregnancy, lactation, unable to understand the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Pancreatits	No intervention, observation	Patients with pancreatitis based ont the Atlanta criteria

Primary Outcome Measures

Name	Time	Method
Se-osteopontin	Within 3 days from diagnosis	Se-osteopontin will be measured at admission and on day 2 and 3 of hospital stay. The change over time will be correlated to severety of pancreatitis as classified in the current Atlanta classification.

Trial Locations

Locations (1)

Linkoping University Hospital; 🇸🇪 Linköping, Sweden